Avant begins second pediatric TP10 trial

AVAN began a second placebo-controlled U.S. Phase IIb trial of its TP10 complement C3/ C5 convertase inhibitor in 30 infants under 1 year of age undergoing cardiac surgery with cardiopulmonary bypass ...